xBoston hedge fund manager Baupost Group grew its portfolio of U.S. stocks by17 percent to $4.14 billion in the first quarter, maintaining large positions in several companies, including Cambridge-based Idenix Pharmaceuticals Inc (NASDAQ:IDIX). Idenix Pharmaceuticals Inc (NASDAQ:IDIX) stock performance was 6.06% in last session and finished the day at $6.03. Traded volume was 789,231 shares in the last session and the average volume of the stock remained 1.29 million shares. The beta of the stock remained -0.04. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) insider ownership is 25.11%.

Stock analysts at Jefferies Group dropped their price target on shares of Enzymotec Ltd (NASDAQ:ENZY) from $25.00 to $14.50 in a report issued on Monday. Jefferies Group’s target price would indicate a potential upside of 12.40% from the stock’s previous close. The analysts wrote, “Our $14.50 (down from $25) price target is based on a sector regression, SOTP and DCF models and implies Enzymotec trades at 12.6x 2015E EPS and 8.2x EBITDA.” Enzymotec Ltd (NASDAQ:ENZY) rose 8.53% to $14.00 yesterday on volume of 619,513 shares. The intra-day range of the stock was $12.50 – 14.10. Enzymotec Ltd (NASDAQ:ENZY) has a market capitalization of $301.91 million.

bluebird bio Inc (NASDAQ:BLUE)’s COO Jeffrey Walsh sold 1,500 shares of bluebird bio stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $20.03, for a total transaction of $30,045.00. bluebird bio Inc (NASDAQ:BLUE)’s stock on May 19, 2014 reported a increase 6.16% to the closing price of $26.73. Its fifty two weeks range is $17.03 – 36.25. The total market capitalization recorded $655.20 million. The overall volume in the last trading session was 513,082 shares. In its share capital, bluebird bio Inc (NASDAQ:BLUE) has 24.51 million outstanding shares.

Athersys, Inc. (NASDAQ:ATHX) first quarter 2014 net loss of 15 cents per share was wider than the Zacks Consensus Estimate of a loss of 9 cents. The company had suffered a loss of 18 cents per share in the year-ago quarter. Revenues increased to $0.7 million from $0.3 million recorded a year ago, driven by higher grant revenues. On Monday, shares of Athersys, Inc. (NASDAQ:ATHX) advanced 6.94% to close the day at $1.54. Company return on investment (ROI) is -122.50% and its monthly performance is recorded as -43.59%. Athersys, Inc. (NASDAQ:ATHX) quarterly revenue growth is -59.26%.